ABSTRACT
The SARS-CoV-2 Receptor Binding Domain (RBD) is both the principal target of neutralizing antibodies, and one of the most rapidly evolving domains, which can result in the emergence of immune escape mutations limiting the effectiveness of vaccines and antibody therapeutics. To facilitate surveillance, we developed a rapid, high-throughput, multiplex assay able to assess the inhibitory response of antibodies to 24 RBD natural variants simultaneously. We demonstrate that immune escape can occur through two mechanisms, antibodies that fail to recognize mutations, along with antibodies that have reduced inhibitory capacity due to enhanced variant RBD-ACE2 affinity. A competitive approach where antibodies simultaneously compete with ACE2 for binding to the RBD may therefore more accurately reflect the physiological dynamics of infection. We describe the enhanced affinity of RBD variants N439K, S477N, Q493L, S494P and N501Y to the ACE2 receptor, and demonstrate the ability of this assay to bridge a major gap for SARS-CoV-2 research; informing selection of complementary monoclonal antibody candidates and the rapid identification of immune escape to emerging RBD variants following vaccination or natural infection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Victorian Government and Medical Research Future Fund (MRFF) GNT2002073 (to W.H.T., D.I.G., A.W.C., S.J.K. and A.K.W.), Emergent Ventures Fast Grant (A.W.C.) and the Paul Ramsay Foundation (D.I.G., S.J.K., A.K.W and A.W.C). D.I.G., W.H.T., S.J.K., A.K.W. and A.W.C are supported by NHMRC fellowships. W.H.T. is a Howard Hughes Medical Institute Wellcome Trust International Research Scholar (208693/Z/17/Z). This work was also supported in part by funding from the Jack Ma Foundation (D.I.G, D.F.J.P, A.K.W, K.S, A.W.C). and the A2 Milk Company (KS). KS is supported by an NHMRC Investigator grant. N.A.G. is supported by an ARC DECRA fellowship. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health. The authors acknowledge the Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocols were approved by the University of Melbourne Human Research Ethics Committee
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data is available in the manuscript or in the supplementary materials.
